Top

Published in:

01-04-2017 | Clinical Study

Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide

Authors: Baptiste Pinel, Mathilde Duchesne, Julie Godet, Serge Milin, Antoine Berger, Michel Wager, Lucie Karayan-Tapon

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

A better understanding of the relationship between glioblastomas molecular subtypes and radio-chemotherapy is needed for the development of individualized strategies. In this study, we aimed to assess whether non-homologous end-joining (NHEJ) protein expression is associated and could predict responses to treatment of mesenchymal (MES) and proneural (PN) subtypes. Tumors from 122 patients with a glioblastoma treated at the University Hospital of Poitiers between 2002–2013 by an association of radiotherapy and temozolomide were collected. Among these tumors, 80 were suitable for in situ analysis and were included in TissueMicroArray. The expression of DNA-PKcs, Ku70, Ku80 and CD44, Olig2 (respectively surrogate markers of MES and PN subtypes) were evaluated by immunohistochemistry. The median survival of patients with high and low CD44 expression was 11.9 months (95% CI 7.7–14) and 19.1 months (95% CI 15.2–22.4) respectively (p = 0.008). Median survival of patients with high and low DNA-PKcs levels was 20.0 months (95% CI 15.2–25.3) and 12.9 months (95% CI 9.9–19.5) respectively (p = 0.036). High levels of Olig2, Ku70 and Ku80 tended to be associated with better overall survival but no significant differences were found. Overall survival of class I patients (CD44+ and DNA-PKcs+) was longer than class II (CD44+ and DNA-PKcs− or CD44− and DNA-PKcs+) and class III (CD44− and DNA-PKcs−), (p = 0.005 and 0.003 respectively). High levels of CD44 and DNA-PK are associated with a better survival and better response to radiotherapy and temozolomide and could establish prognosis classes by predicting survival and response to therapy for GBMs patients.

Available only for authorised users

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173CrossRef

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17(1):98CrossRef

Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24(3):331–346CrossRef

Pries R, Witrkopf N, Trenkle T, Nitsch SM, Wollenberg B (2008) Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. Vivo Athens Greece 22(1):89–92

Wang W, Dong L-P, Zhang N, Zhao C-H (2014) Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. Int J Clin Exp Med 7(12):5059–5066PubMedPubMedCentral

Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH et al (2009) Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 59(4):241–246CrossRef

Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV et al (2003) CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res 9(14):5318–5324

Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY et al (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358(9278):298–300CrossRef

10.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760CrossRef

11.

Bouchaert P, Guerif S, Debiais C, Irani J, Fromont G (2012) DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1179–1185CrossRef

12.

Lee S-W, Cho K-J, Park J-H, Kim SY, Nam SY, Lee B-J et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62(5):1451–1457CrossRef

13.

Kase M, Vardja M, Lipping A, Asser T, Jaal J (2011) Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiother Oncol J Eur Soc Ther Radiol Oncol 101(1):127–131CrossRef

14.

Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol 6(3):227–235CrossRef

15.

Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRef

16.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773.CrossRef

17.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718CrossRef

18.

Wei K-C, Huang C-Y, Chen P-Y, Feng L-Y, Wu T-WE, Chen S-M et al (2010) Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30(1):253–259PubMed

19.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL et al (2015) Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol Off J Am Soc Clin Oncol 33(25):2735–2744CrossRef

20.

Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A et al (2014) A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis 3(3):e91CrossRef

21.

Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB et al (2009) Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4):1251–1255CrossRef

22.

Hine CM, Seluanov A, Gorbunova V (2008) Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 105(52):20810–20815CrossRef

Title: Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide
Authors: Baptiste Pinel
Mathilde Duchesne
Julie Godet
Serge Milin
Antoine Berger
Michel Wager
Lucie Karayan-Tapon
Publication date: 01-04-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2367-7

At a glance: The STEP trials

Springer Medicine

Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells

The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease

Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas

Early postoperative tumor progression predicts clinical outcome in glioblastoma—implication for clinical trials

Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status

Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer